



Contacts: Bret L. Udem
Media Relations
Tel. (425) 493-2293
Fax. (425) 493-2010

FOR RELEASE
July 27, 2004

DR. CRAIG PARMAN OF AGILIX PRESENTS DATA DEMONSTRATING THE IDENTIFICATION AND DISCOVERY OF LOW EXPRESSED GENES USING COMBIMATRIX'S CUSTOMARRAY™ PLATFORM

Newport Beach, Calif. – (BUSINESS WIRE) –July 27, 2004 – Acacia Research Corporation (Nasdaq: CBMX:ACTG) announced today a customer of its CombiMatrix group, Dr. Craig Parman, Vice President of Genomics at Agilix, will present data obtained on CombiMatrix's CustomArrays™ at the BioArrays-2004 Meeting in New York today. The presentation will take place at 3:15 PM EST, at the Holiday Inn Midtown in New York.

“The customizability, flexibility, sensitivity, and reproducibility inherent in the CombiMatrix CustomArrays have enabled our research team to extend the capabilities of our GenCompass™ technology for genome-wide studies to important new applications. This technique is capable of detecting low expressed, known, and novel genes, from any organism,” said Dr. Craig Parman, Vice President of Genomics at Agilix. “A key component to the discovery process is an efficient and cost effective method for verification. The flexibility and sensitivity of CombiMatrix's CustomArrays is ideal for our application.”

“We are pleased to see Agilix presenting their results obtained using our products,” said Dr. Amit Kumar, CEO and President of CombiMatrix Corporation. “A necessary component in the roll-out of new products in the biotech industry is the presentation, either oral or published, of third-party data using the product. As customers continue to use our products, we look forward to additional presentations and peer-reviewed articles, helping to establish the credibility and utility of our CustomArray products.”

ABOUT CUSTOMARRAY™

CustomArrays™ are semiconductor-based arrays (approx. 1 cm²) integrated onto a standard 1” x 3” slide format. CombiMatrix synthesizes oligonucleotides *in situ* to build CustomArrays. This revolutionary technology allows CombiMatrix to deliver CustomArrays in days. Sensitivity and performance metrics are available on the company's main web site and at www.customarray.com.

Researchers can place orders for CustomArray products by contacting CombiMatrix at (800) 985-2269 or by accessing CombiMatrix's order site at www.customarray.com.

ABOUT AGILIX

Agilix Corporation is a leading developer of functional genomics and proteomics platform technologies to aid in the discovery and analysis of genes, their protein products and related biological functions. The Company's services help reduce the risk, cost and time to market for new pharmaceutical, biotechnology and agricultural products. Agilix is headquartered in New Haven, Connecticut. Information about Agilix Corporation is available at www.agilixcorp.com.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications including DNA synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical detection. CombiMatrix provides DNA arrays to researchers under the CustomArray™ brand. CombiMatrix's Express Tracksm drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds.

The Acacia Technologies Group develops, acquires, and licenses patented technologies. Acacia's DMT technology, which is supported by 5 U.S. and 31 foreign patents, relates to audio and audio/video transmission and receiving systems commonly known as audio-on-demand, video-on-demand, and audio/video streaming, and is used for distributing digital content via several means including Internet, cable, satellite and wireless systems.

Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia Research-CombiMatrix (Nasdaq: CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.